PHARMA COMPANIES
Strides Founder raises Rs 1000 crore to refinance debt
Arun Kumar, founder of Strides Group and OneSource, has secured ₹1,000 crore by pledging shares. This move refinances existing loans, extending maturities and simplifying repayments. The transaction aims to consolidate smaller borrowings into larger, long-term facilities. It reflects a broader effort to clean up the promoter's balance sheet and shows a decline in pledged shares, indicating deleveraging.
Roche Vs Natco: Supreme Court clears decks for launch of Natco Pharma's Risdiplam generic in India
The Supreme Court has allowed Natco Pharma to launch its generic version of the spinal muscular atrophy drug Risdiplam in India, dismissing F. Hoffmann-La Roche's appeal. The court upheld the Delhi High Court's decision, which prioritized public access to the life-saving medication at a significantly lower price.
PSU push: From rare earths to shipbuilding, Ramesh Damani on 3 sectors to watch for the next decade
BSE member Ramesh Damani says India’s shift to state-directed capex — from defence and rare earths to shipbuilding and urban redevelopment — will form the next decade’s profit pools. He urges active stock picking, long-term equity bets for grandchildren, and selective exposure to pharma and strategic PSUs as Samvat 2082 investment themes.
Pharma companies announce direct-to-consumer sales and price cuts in US
Several pharmaceutical companies are now selling drugs directly to U.S. patients and offering significant discounts, responding to President Trump's push to lower prescription costs and eliminate intermediaries. These initiatives include deals for tariff relief in exchange for price reductions and the launch of new direct-to-consumer sales platforms.
Indian firms explore localisation of pharma production in Russia
The Russian market is attracting growing interest from Indian pharmaceutical companies exploring opportunities to establish production facilities across various regions of the country. This was announced by Moscow Government Minister and Head of the Department for External Economic and International Relations, Sergey Cheremin, during the " Russia-India. Mutual Efficiency" forum.
Healthy start! Rubicon Research shares list at 28% premium over IPO price
Rubicon Research Share Price debuted on stock exchanges with a significant 27.9% premium, opening at Rs 620. The Rs 1,377 crore IPO saw overwhelming demand, subscribed 109 times, driven by strong QIB interest. Analysts cite robust financials, a specialized US generics portfolio, and a scalable model for the excitement.
- Go To Page 1
Graph AI raises $3 million seed funding for drug safety platform
AI life sciences startup Graph AI has secured $3 million in seed funding to revolutionise pharmacovigilance. The California-based startup leverages AI-driven automation to address the inefficiencies and errors in traditional drug safety monitoring. This funding will accelerate product innovation and global market expansion for their SaaS platform.
Torrent Pharma plans Rs 14,000 crore bond sale for JB Chemicals acquisition
Torrent Pharmaceuticals is planning a ₹14,000-crore bond sale to finance its acquisition of JB Chemicals & Pharmaceuticals. The company is in discussions with major banks for the funding package, which will be repaid through internal accruals. The proposed merger is awaiting regulatory approvals.
Under the scanner, yet generic cough syrups hit shelves
Worry is spreading regarding the multitude of cough syrup brands circulating in India, with alarming revelations of toxic diethylene glycol detected in some, resulting in heartbreaking instances of child mortality. This situation sheds light on the questionable efficacy of regulatory measures, as many small-scale producers evade scrutiny.
MP: Coldrif cough syrup fatality count rises to 24 after two more children die
Tragedy strikes Chhindwara as two more children die from adulterated cough syrup. The death toll now stands at 24. The victims, aged three years and nine months, succumbed to suspected renal failure in Nagpur. The WHO issued an alert against substandard cough syrups. Authorities have banned the formulation and arrested individuals involved. Manufacturing licenses have been revoked.
Rohit Srivastava's Diwali 2025 strategy: Nifty poised for breakout; buy growth, not defensives
Rohit Srivastava of Strike Money Analytics says Indian markets are set for a breakout as Nifty eyes 26,300. He expects earnings growth to pick up on policy support and liquidity infusion, urging investors to avoid defensives like IT and FMCG and focus instead on financials, autos, metals, power, and real estate.
Gold may glitter, but equities shine brighter; SMEs, NBFCs & niche manufacturing to drive wealth creation: Madhusudan Kela
Market veteran Madhusudan Kela says India’s markets are set for an earnings-led upmove as liquidity, policy support, and AI-driven growth kick in. He’s bullish on AI, power, manufacturing, NBFCs, and SME entrepreneurship, urging investors to stay patient and selective for the next phase of India’s equity story in Samvat 2082.
CDSCO seeks views on level playing field for new drugs
In a significant shift for the pharmaceutical market, India's drug regulator is crafting new legislation regarding drug approvals. Under this proposal, the first entity to introduce a novel drug will be mandated to perform clinical trials, while subsequent entrants will be allowed to forego these tests.
Roche moves SC against Natco’s launch of generic Risdiplam in India
F. Hoffmann-La Roche AG has approached the Supreme Court. This follows a Delhi High Court decision permitting Natco Pharma to introduce a generic version of Risdiplam. Risdiplam treats spinal muscular atrophy. The High Court rejected Roche's plea to halt Natco's manufacturing. Natco plans to sell the drug at a significantly lower price.
India accuses Balaji Amines of making pharma-grade chemical without a drug-making licence
Balaji Amines faces accusations from Indian authorities for producing pharma-grade propylene glycol without a necessary drug manufacturing license. This comes after some batches were found to be substandard. The company states it only manufactured technical and food-grade PG for non-pharma clients. Investigations are ongoing, and the company's stock has seen a decline.
Rubicon Research IPO allotment date today: GMP at Rs 95; How to check status on BSE and MUFG Intime
Rubicon Research IPO Allotment Status: Rubicon Research's Rs 1,377 crore IPO concluded with strong investor demand, oversubscribing 109.35 times. The share allotment is scheduled for October 14, with the company set to list on the BSE and NSE on October 16. The pharmaceutical firm's robust financial performance and differentiated product portfolio are driving positive market sentiment.
Aurobindo Pharma promoters raise Rs 2k cr to fund realty, other asset buys
The transaction is split into two parts. The Rs 650 crore Series 1 comes with a 24-month tenor and a two-year put and call option, and Rs 1,450 crore, which will be Series 2 with a four-year tenor. Series 1 will carry a coupon of 11.75%, while Series 2 is likely to be priced at 15.5%.
With the tariff threat headache over, time to focus on them again? 8 pharma stocks with upside potential of up to 39%
With a clear indication that no additional or special tariff will be imposed by the US on generic drugs, there is a sense of relief among Indian drug companies. The US healthcare system, too, must be relieved, given that India is the biggest supplier of generic drugs to the American market. Any increase in the cost of these medicines would have led to a disruption in the US healthcare system. Now that the tariff threat – which has been troubling Indian companies for the past year – is seemingly a thing of the past, will things get better on the street for Indian pharma companies?
Pharma companies announce direct-to-consumer sales and price cuts in US
Several drug makers are now selling medicines directly to Americans. This move follows President Trump's push to reduce prescription drug prices. Companies like AbbVie, AstraZeneca, and Pfizer are offering discounts. A new government website, TrumpRx.gov, is planned for early 2026. Patients will soon have more options to access affordable medications.
Cough Syrup deaths: Sresan Pharmaceuticals' license cancelled, company shut down
Tamil Nadu has cancelled the manufacturing license of Sresan Pharmaceutical, maker of Coldrif cough syrup, after it was linked to at least 22 deaths in Madhya Pradesh due to toxic contaminants. The state ordered comprehensive inspections of all pharmaceutical units following the incident and the arrest of the company owner.
ED raids seven Chennai sites linked to Sresan Pharma over Coldrif cough syrup deaths
The Enforcement Directorate (ED) conducted searches at seven locations in Chennai concerning the Coldrif cough syrup case. These raids, under the PMLA, are linked to Sresan Pharma, the manufacturer of the banned syrup. The cough syrup has been linked to the deaths of approximately 22 children, primarily in Madhya Pradesh and Rajasthan.
MP police registers FIR against Sresan Pharma, links deaths of children directly to the company
Madhya Pradesh police have registered an FIR against Sresan Pharma for allegedly adulterated Coldrif syrup, linked to the deaths of 21 children. The proprietor was arrested, and the Enforcement Directorate is conducting searches in Chennai. Investigations reveal significant lapses by the Tamil Nadu FDA in regulatory oversight.
Can US generics momentum and CDMO strength keep pharma earnings steady this quarter?
Indian pharmaceutical companies are set for a steady September quarter. Growth in the US generics market and domestic sales will drive performance. Companies like Apollo Hospitals, Lupin, and Aurobindo are expected to show strong results. Despite some cost pressures, the sector anticipates positive medium-term prospects. New product launches and expanding facilities will support earnings.
Natco Pharma to acquire significant stake in S African firm Adcock Ingram
Indian pharmaceutical company Natco Pharma is set to acquire significant stakes in South Africa's Adcock Ingram, a 135-year-old firm, in a R4.2 billion deal. This acquisition will make Adcock Ingram a privately-held entity, co-owned by Natco and Bidvest, with Adcock Ingram delisting from the JSE post-completion.
Cough syrup deaths: Probe against Coldrif manufacturer exposed lapses by TNFDA
Lapses by the Tamil Nadu Food and Drug Administration in enforcing basic regulatory norms have been exposed following the deaths of children linked to a cough syrup. The manufacturer, Sresan Pharma, operated for over a decade with poor infrastructure and multiple violations, with the state FDA failing to inform the central drug regulator about its operations and audits.
Tariff pause eases pressure on drug companies
Indian drug makers can breathe easier as the US reportedly shelves plans for tariffs on generic drug imports. This move is a significant relief for Indian pharmaceutical companies, which supply nearly half of all generic prescriptions in the United States. Experts believe the US recognized the potential for price hikes and drug shortages for its own citizens.
Delhi HC allows Natco Pharma to launch risdiplam, rejects Roche plea
The Delhi High Court has permitted Natco Pharma to launch its affordable generic version of risdiplam, a crucial drug for spinal muscular atrophy. This decision overturns a previous stay, allowing Natco to offer the medication at a significantly lower price than Swiss multinational Roche's imported Evrysdi. Roche expressed disappointment, emphasizing the importance of patent protection for innovation.
'Our govt will not spare the accused,' says MP CM Mohan Yadav on arrest of Sresan Pharma Owner
Madhya Pradesh Chief Minister Mohan Yadav has vowed strict action against all accused in the Chhindwara cough syrup deaths. The owner of Tamil Nadu-based Sresan Pharmaceuticals, manufacturer of the implicated Coldrif cough syrup, has been arrested. The state government is actively investigating and ensuring such incidents are prevented in the future.
Trump & Co said to have shelved generic drug tariffs, Indian pharma stocks get booster dose
The Trump White House has halted plans for tariffs on generic drug imports, a decision welcomed by Indian pharma companies that supply nearly half of US generic prescriptions. This move reassures millions of Americans relying on affordable imported medications for various health conditions, averting potential price hikes and shortages.
Load More
